Catalyst Pharmaceuticals Partners, Inc. (CPRX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$31.490.00%
Close 2026-07-16 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · CPRX
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How this business ranks within health care on a research-validated quality screen. As of 2026-07-24.
The screen ranks CPRX against its sector on four durable signals: share dilution, return on capital, free-cash-flow yield, and FCF margin. Historically the highest-quality names tended toward better typical outcomes and fewer bad years over multi-year holds (strongest at three years, modest at one), and that pattern showed up even before the price moved. It characterizes business quality, not price direction.
Each leg is a sector-relative percentile (higher is better); 4 of 4 legs were available for this name. The composite is built from these four; the raw value follows each percentile for context.
A forward quality tilt, not a price prediction, and context for your own research rather than a recommendation. Not investment advice.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 53% of the time over the next year (vs 41% for the rest of the cohort, n=9986).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Complete the merger with Angelini Pharma to expand Catalyst's portfolio and global footprint.
Stated as a priority in 2 of last 2 quarters. Management announced the merger agreement with Angelini Pharma in 2026-Q1 and completed the acquisition by 2026-Q2. This strategic expansion is recent and delivering as planned with the merger consummated.
“Completion of Acquisition or Disposition of Assets related to Angelini Pharma merger announced on May 6, 2026.”
“Catalyst will not provide forward-looking guidance following May 7, 2026 announcement of merger with Angelini Pharma.”
Settle ongoing patent litigation related to FIRDAPSE to protect market exclusivity and revenue streams.
Stated as a priority in 2 of last 2 quarters. The company settled patent litigation with Hetero USA in 2026-Q1, following prior settlements with other parties in 2025-Q4. This shows progress in resolving patent disputes to protect product exclusivity.
“Settlement agreement with Hetero USA announced resolving patent litigation on May 7, 2026.”
Drive organic growth of flagship products FIRDAPSE and AGAMREE to increase total revenues and profitability.
Stated as a priority in 3 of last 3 quarters. Total revenues grew from $489.3M in 2024 to $589.0M in 2025 (19.8% growth), with Q1 2026 revenues at $149.4M, up 5.6% YoY. GAAP net income increased 30.8% from $163.9M in 2024 to $214.3M in 2025. The trajectory is delivering consistent organic growth in revenues and profitability.
“Q1 2026 total revenues of $149.4M, up 5.6% YoY; FIRDAPSE revenue up 18.1%, AGAMREE up 66.6%.”
Repurchase up to $200 million of common stock by end of 2026 to return capital to shareholders.
Stated as a priority in 2 of last 2 quarters. The company announced a $200 million share repurchase program in 2025-Q4 and invested approximately $25.3 million in Q4 2025. The program remains active through 2026, showing ongoing execution though no new quarterly amounts disclosed yet.
Advance clinical development of vamorolone demonstrating glucocorticoid activity without significant immunosuppression.
Newly stated in 2026-Q2. The Phase 1 clinical study results released in mid-2026 show vamorolone's favorable profile with expected glucocorticoid activity and minimal immunosuppression at clinical doses. This is an early-stage development priority with initial clinical data supporting its potential.
Over the trailing year it converted 1.16x of net income into operating cash flow. Historically, Health Care names rated neutral grew net income 54% of the time over the next year (vs 43% for the rest of the cohort, n=3313).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, Fed net liquidity, long-term interest rates (low R² over the window).
15 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated volatile grew net income 53% of the time over the next year (vs 50% for the rest of the cohort, n=3986).
Not investment advice. As of 2026-09-04.
“Patent litigation with Teva and Lupin settled; only Hetero USA case pending with trial scheduled for March 2026.”
“Q4 2025 total revenues $152.6M, up 7.6% YoY; FIRDAPSE up 18.3%, AGAMREE up 67.5%.”
“Full year 2025 total revenues $589.0M, up 19.8% YoY; FIRDAPSE $358.4M, AGAMREE $117.1M.”
“No new guidance on repurchase program; program ongoing through 2026.”
“Announced $200 million share repurchase program with $25.3 million spent in Q4 2025.”